Statin-Ezetimibe Combination vs. Statin Monotherapy in ASCVD: Insights from the Ez-PAVE Trial

Highlight

  • Initial statin-ezetimibe combination therapy lowers LDL cholesterol more effectively than statin monotherapy among patients with atherosclerotic cardiovascular disease (ASCVD).
  • No significant difference in the 3-year composite risk of major cardiovascular events between combination therapy and monotherapy groups.
  • Combination therapy facilitates achieving lower LDL-C targets within both intensive and conventional LDL-C-targeting strategies.
  • Safety profiles of combination therapy and monotherapy are comparable over the 3-year follow-up.

Study Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply